Cargando…
Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
Autores principales: | Kow, Chia Siang, Abdul Sattar Burud, Ismail, Hasan, Syed Shahzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mayo Foundation for Medical Education and Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934659/ https://www.ncbi.nlm.nih.gov/pubmed/33958065 http://dx.doi.org/10.1016/j.mayocp.2021.03.001 |
Ejemplares similares
-
A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021) -
Famotidine: A potential mitigator of mast cell activation in post-COVID-19 cognitive impairment
por: Kow, Chia Siang, et al.
Publicado: (2023) -
In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
por: Lavie, Carl J.
Publicado: (2021) -
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis
por: Kow, Chia Siang, et al.
Publicado: (2021) -
Azithromycin in patients with COVID-19: Friend or foe?
por: Kow, Chia Siang, et al.
Publicado: (2021)